B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 59.1%

Neg 59.1% Neu 0% Pos 0%

B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.